ALKS Stock Analysis: Alkermes | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 7.712m USD | 12M Return: 41.4% | IE00B56GVS15 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 75.2M
EPS Trend: -8.6%
Qual. Beats: 0
Rev. Trend: 7.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alkermes plc (NASDAQ: ALKS) is a Dublin-based biopharmaceutical company that develops and commercializes medicines targeting central nervous system and addiction-related disorders, primarily in the United States and Ireland. Founded in 1987, the company markets a portfolio that includes ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for narcolepsy-related symptoms. The company also licenses proprietary drug delivery and formulation technology platforms to third parties and maintains collaboration agreements with Janssen Pharmaceutica entities.
As a mid-cap biotechnology company, Alkermes operates in the highly competitive CNS therapeutics space, where development cycles are long and revenue is dependent on a relatively small number of approved products. The companys business model combines direct commercialization of proprietary drugs with technology licensing arrangements, which can provide more stable royalty or milestone income alongside product sales.
- VIVITROL and ARISTADA sales anchor base revenue
- LYBALVI and LUMRYZ launches expand psychiatry and sleep franchise
- ARISTADA faces generic competition pressuring market share
| Net Income: -351k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -15.95 > 1.0 |
| NWC/Revenue: 52.97% < 20% (prev 83.30%; Δ -30.34% < -1%) |
| CFO/TA 0.05 > 3% & CFO 243.0m > Net Income -351k |
| Net Debt (886.9m) to EBITDA (178.7m): 4.96 < 3 |
| Current Ratio: 2.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (176.4m) vs 12m ago 4.66% < -2% |
| Gross Margin: 82.89% > 18% (prev 86.04%; Δ -3.16% > 0.5%) |
| Asset Turnover: 51.84% > 50% (prev 65.31%; Δ -13.46% > 0%) |
| Interest Coverage Ratio: 1.13 > 6 (EBIT TTM 98.0m / Interest Expense TTM 86.6m) |
| A: 0.21 (Total Current Assets 1.58b - Total Current Liabilities 651.9m) / Total Assets 4.44b |
| B: -0.18 (Retained Earnings -784.5m / Total Assets 4.44b) |
| C: 0.03 (EBIT TTM 98.0m / Avg Total Assets 3.38b) |
| D: 0.73 (Book Value of Equity 1.86b / Total Liabilities 2.57b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 1.12 (Receivables 459.1m/355.1m, Revenue 1.75b/1.52b) |
| GMI: 1.04 (GM 86.04% / 82.89%) |
| AQI: 5.14 (AQ_t 0.58 / AQ_t-1 0.11) |
| SGI: 1.15 (Revenue 1.75b / 1.52b) |
| TATA: -0.05 (NI -351k - CFO 243.0m) / TA 4.44b) |
| Beneish M = -0.33 (Cap -4..+1) = D |
As of November 10, 2026, the stock is trading at USD 46.17 with a total of 1,708,119 shares traded. Over the past week, the price has changed by +2.85%, over one month by +13.69%, over three months by -6.54% and over the past year by +41.41%.
Current recommended Stop Loss: 42.70 (which is 7.5% or 2.1 ATR below the current price).
Alkermes has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy ALKS.
- StrongBuy: 12
- Buy: 3
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 56.2 | 21.7% |
P/E Forward = 133.3333
P/S = 4.6242
P/B = 4.242
P/EG = 1.9605
Revenue TTM = 1.75b USD
EBIT TTM = 98.0m USD
EBITDA TTM = 178.7m USD
Long Term Debt = 1.54b USD (estimated: total debt 1.57b - short term 34.1m)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 1.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 71.3m
Net Debt = 886.9m USD (calculated: Debt 1.64b - CCE 755.5m)
Enterprise Value = 8.60b USD (7.71b + Debt 1.64b - CCE 755.5m)
Interest Coverage Ratio = 1.13 (Ebit TTM 98.0m / Interest Expense TTM 86.6m)
EV/FCF = 37.82x (Enterprise Value 8.60b / FCF TTM 227.4m)
FCF Yield = 2.64% (FCF TTM 227.4m / Enterprise Value 8.60b)
FCF Margin = 12.97% (FCF TTM 227.4m / Revenue TTM 1.75b)
Net Margin = -0.02% (Net Income TTM -351k / Revenue TTM 1.75b)
Gross Margin = 82.89% ((Revenue TTM 1.75b - Cost of Revenue TTM 300.1m) / Revenue TTM)
Gross Margin QoQ = 80.38% (prev 80.22%)
Tobins Q-Ratio = 1.94 (Enterprise Value 8.60b / Total Assets 4.44b)
Interest Expense / Debt = 5.28% (Interest Expense 86.6m / Debt 1.64b)
Taxrate = 17.08% (49.8m / 291.4m)
NOPAT = 81.2m (EBIT 98.0m * (1 - 17.08%))
Current Ratio = 2.42 (Total Current Assets 1.58b / Total Current Liabilities 651.9m)
Debt / Equity = 0.88 (Debt 1.64b / totalStockholderEquity, last quarter 1.86b)
Debt / EBITDA = 4.96 (Net Debt 886.9m / EBITDA 178.7m)
Debt / FCF = 3.90 (Net Debt 886.9m / FCF TTM 227.4m)
Total Stockholder Equity = 1.81b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.01% (Net Income -351k / Total Assets 4.44b)
RoE = -0.02% (Net Income TTM -351k / Total Stockholder Equity 1.81b)
RoCE = 2.93% (EBIT 98.0m / Capital Employed (Equity 1.81b + L.T.Debt 1.54b))
RoIC = 2.18% (NOPAT 81.2m / Invested Capital 3.73b)
WACC = 7.63% (E(7.71b)/V(9.35b) * Re(8.32%) + D(1.64b)/V(9.35b) * Rd(5.28%) * (1-Tc(0.17)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.75 | Cagr: 1.39%
[DCF] Terminal Value 73.10% ; FCFF base≈332.8m ; Y1≈291.8m ; Y5≈235.8m
[DCF] Fair Price = 17.24 (EV 3.78b - Net Debt 886.9m = Equity 2.90b / Shares 168.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -8.65 | EPS CAGR: -2.48% | SUE: 0.76 | # QB: 0
Revenue Correlation: 7.25 | Revenue CAGR: 0.48% | SUE: 0.75 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.06 | Chg30d=+57.04% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=1.27 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-39.2% | GrowthRev=+23.5%
EPS next Year (2027-12-31): EPS=1.81 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+41.8% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +0% (up=2, down=2)